{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-025196","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.439062+00:00","generated_at":"2026-06-05T23:16:17.493351+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bicycle Therapeutics Q4 net loss $49.1M; cash $526.4M; BT8009 Phase 2/3 trial recruiting","bullets":["Net loss $49.1M ($1.16/share) in Q4 2023 vs $30.0M prior year; full year loss $180.7M ($5.08).","Cash $526.4M as of Dec 31, 2023, up from $339.2M; financial runway expected into 2026.","BT8009 Phase 2/3 Duravelo-2 registrational trial for metastatic urothelial cancer now active and recruiting.","BT8009 showed 38% objective response rate in EV-naïve mUC patients; differentiated safety profile.","Stephen Sands appointed to Board; former chairman of Lazard's Global Healthcare Group, serves on Audit and Strategic Committees."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-025196","json":"https://secwatch.observer/filing/0001104659-24-025196.json","markdown":"https://secwatch.observer/filing/0001104659-24-025196.md","text":"https://secwatch.observer/filing/0001104659-24-025196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465924025196/0001104659-24-025196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465924025196/tm246555d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T23:16:17.493351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9e8ea1734cedade793d3e62b7762d8dfb5444e4c","claim":"BICYCLE THERAPEUTICS PLC reported financial results for the fiscal quarter and the year ended December 31, 2023.","evidence_excerpt":"On February 20, 2024, Bicycle Therapeutics plc (the “Company”) issued a press release announcing financial results for the fiscal quarter and the year ended December 31, 2023 and other business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465924025196/0001104659-24-025196-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter and the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"db00214e19","claim":"Stephen Sands was appointed as Director at BICYCLE THERAPEUTICS PLC.","evidence_excerpt":"On February 20, 2024, the Board of Directors (the “Board”) of the Company, upon the recommendation of the Nominating & Corporate Governance Committee of the Board, appointed Stephen Sands to the Board, effective as of the close of business on February 20, 2024, New York City time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465924025196/0001104659-24-025196-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}